摘要
目的探讨阿戈美拉汀对产后抑郁伴睡眠障碍患者的抑郁情绪及睡眠质量的影响。方法选取2018年1月~2020年5月我院123例产后抑郁伴睡眠障碍患者,按照随机抽样法分成两组,对照组61例患者给予帕罗西汀口服,观察组62例患者给予阿戈美拉汀口服,治疗3个月后对比两组患者血清氧化应激因子、抑郁情绪、睡眠质量、药物安全性。结果两组患者治疗后丙二醇(MDA)水平均下降,超氧化物歧化酶(SOD)水平均上升,但观察组下降、上升幅度均高于对照组(P<0.05);两组治疗后爱丁堡产后抑郁量表(EPDS)评分、匹兹堡睡眠指数(PSQI)评分均下降,但观察组评分下降幅度高于对照组(P<0.05);观察组总不良反应发生率3.23%(2/62)低于对照组8.20%(5/61)(P>0.05)。结论阿戈美拉汀治疗产后抑郁伴睡眠障碍患者的效果确切,能够显著缓解患者的抑郁情绪,改善患者的睡眠质量,降低患者体内血清氧化应激因子,安全性好。
Objective To explore the effects of agormelatin on depression and sleep quality in patients with postpartum depression and sleep disorders.Methods From January2018 to May 2020,123 patients with postpartum depression and sleep disorders were divided into two groups according to random sampling method,61 patients in the control group were given oral paroxetine,62 patients in the observation group were given agomelatin orthopaedic.The serum oxidative stress factors,depression,sleep quality and drug safety were compared between two groups at the end of 3 months of treatment.Results The Malondial dehyde(MDA)level decreased and Superoxide dismutase(SOD)level increased after treatment in both groups,but the decline or increase in the observation group were higher than that of the control group(P<0.05).The total rate of adverse reactions in the observation group was 3.23%(2/62),which was lower than that in the control group of 8.20%(5/61)(P>0.05).Conclusion The effect of aggomeilatin in treating postpartum depression patients with sleep disorder is good,which can significantly relieve the patient's depression,improve the patient's sleep quality,reduce their serum oxidative stress factor with high safety.
作者
丁青
曹蒙
周辉
居春阳
DING Qing;CAO Meng;ZHOU Hui(Xuchang Central Hospital,Xuchang 461000,China)
出处
《国际精神病学杂志》
2021年第5期840-842,854,共4页
Journal Of International Psychiatry
